206 related articles for article (PubMed ID: 32387281)
1. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
4. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
5. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
6. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
Hellman JB; Traynis I; Lin LK
Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.
Touat M; Maisonobe T; Knauss S; Ben Hadj Salem O; Hervier B; Auré K; Szwebel TA; Kramkimel N; Lethrosne C; Bruch JF; Laly P; Cadranel J; Weiss N; Béhin A; Allenbach Y; Benveniste O; Lenglet T; Psimaras D; Stenzel W; Léonard-Louis S
Neurology; 2018 Sep; 91(10):e985-e994. PubMed ID: 30089619
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
12. Diaphragm involvement in immune checkpoint inhibitor-related myositis.
Sekiguchi K; Hashimoto R; Noda Y; Tachibana H; Otsuka Y; Chihara N; Shiraishi Y; Inoue T; Ueda T
Muscle Nerve; 2019 Oct; 60(4):E23-E25. PubMed ID: 31323130
[No Abstract] [Full Text] [Related]
13. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory myopathy associated with PD-1 inhibitors.
Seki M; Uruha A; Ohnuki Y; Kamada S; Noda T; Onda A; Ohira M; Isami A; Hiramatsu S; Hibino M; Nakane S; Noda S; Yutani S; Hanazono A; Yaguchi H; Takao M; Shiina T; Katsuno M; Nakahara J; Matsubara S; Nishino I; Suzuki S
J Autoimmun; 2019 Jun; 100():105-113. PubMed ID: 30862448
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma.
Hamada S; Fuseya Y; Tsukino M
Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):346-348. PubMed ID: 29496287
[No Abstract] [Full Text] [Related]
17. Ocular myositis and neuromyositis.
Ricker K; Pohlenz S
Eur Neurol; 1968; 1(1):41-9. PubMed ID: 5687350
[No Abstract] [Full Text] [Related]
18. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
[TBL] [Abstract][Full Text] [Related]
20. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]